Cargando…

Resistance mechanisms in BRAF(V600E) paediatric high-grade glioma and current therapeutic approaches

Paediatric high-grade gliomas (pHGG) are aggressive central nervous system tumours with a poor prognosis. BRAF(V600E) mutant pHGGs can be treated with targeted BRAF inhibitors, which have shown both preclinical activity and potent clinical efficacy. Unfortunately, the development of drug resistance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lehmann, R., Rayner, B. S., Ziegler, D. S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792688/ https://www.ncbi.nlm.nih.gov/pubmed/36582791 http://dx.doi.org/10.3389/fonc.2022.1031378

Ejemplares similares

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Response and resistance to BRAF(V600E) inhibition in gliomas: Roadblocks ahead?
por: Capogiri, Monica, et al.
Publicado: (2023)

Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
por: Di Nunno, Vincenzo, et al.
Publicado: (2023)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas
por: Penman, Catherine Louise, et al.
Publicado: (2015)

LGG-23. OUTCOMES UTILIZING BRAF INHIBITION MONOTHERAPY IN BRAF(V600E) MUTATED PEDIATRIC LOW GRADE GLIOMAS
por: McThenia, Sheila, et al.
Publicado: (2023)

Sustained response of three pediatric BRAF(V600E) mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy
por: Toll, Stephanie A., et al.
Publicado: (2019)

Addendum: Sustained response of three pediatric BRAF(V600E) mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy
por: Toll, Stephanie A., et al.
Publicado: (2023)

BRAF (AMP) Frequently Co-occurs With IDH1/2, TP53, and ATRX Mutations in Adult Patients With Gliomas and Is Associated With Poorer Survival Than That of Patients Harboring BRAF (V600E)
por: Da, Rong, et al.
Publicado: (2021)

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)

Successes and challenges in modeling heterogeneous BRAF(V600E) mutated central nervous system neoplasms
por: Xing, Yao Lulu, et al.
Publicado: (2023)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

DRP1 Promotes BRAF(V600E)-Driven Tumor Progression and Metabolic Reprogramming in Colorectal Cancer
por: Padder, Rayees Ahmad, et al.
Publicado: (2021)

Melanotic Neuroectodermal Tumor of Infancy: A Clinicopathological and BRAF V600E Mutation Study of 11 Cases
por: Xia, Rong-Hui, et al.
Publicado: (2021)

Metanephric stromal tumor with BRAF V600E mutation in an adult patient: Case report and literature review
por: Fan, Yuqian, et al.
Publicado: (2022)

Blood-Based Detection of BRAF V600E in Gliomas and Brain Tumor Metastasis
por: Kang, Keiko M., et al.
Publicado: (2021)

Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report
por: Piccolo, Gianluca, et al.
Publicado: (2022)

An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer
por: Xue, Yaohua, et al.
Publicado: (2017)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

GLI1 Inhibitor SRI-38832 Attenuates Chemotherapeutic Resistance by Downregulating NBS1 Transcription in BRAF(V600E) Colorectal Cancer
por: Zhang, Ruowen, et al.
Publicado: (2020)

EGFR blockade prevents glioma escape from BRAF(V600E) targeted therapy
por: Yao, Tsun-Wen, et al.
Publicado: (2015)

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
por: Burger, Michael C., et al.
Publicado: (2017)

HGG-02. ADOLESCENT AND YOUNG ADULT (AYA) GLIOMA WITH BRAF V600E-MUTANTATION
por: Kimura, Yui, et al.
Publicado: (2020)

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma
por: Bouffet, Eric, et al.
Publicado: (2023)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma
por: Gabler, Lisa, et al.
Publicado: (2019)

Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas
por: Fusco, Michael J., et al.
Publicado: (2021)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report
por: Zelli, Veronica, et al.
Publicado: (2022)

Colorectal cancer in patients of advanced age is associated with increased incidence of BRAF p.V600E mutation and mismatch repair deficiency
por: Christenson, Eric S., et al.
Publicado: (2023)

LGG-12. SAFETY AND EFFICACY OF DUAL THERAPY WITH DABRAFENIB AND TRAMETINIB IN AN INFANT WITH BRAF V600E MUTANT INOPERABLE LOW GRADE GLIOMA
por: Green, Sage, et al.
Publicado: (2021)

Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation
por: Liu, Chaoyuan, et al.
Publicado: (2022)

BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications
por: Dias-Santagata, Dora, et al.
Publicado: (2011)

BRAF(V600E )mutations in malignant melanoma are associated with increased expressions of BAALC
por: Schrama, David, et al.
Publicado: (2008)

Prolonged Response Induced by Single Agent Vemurafenib in a BRAF V600E Spinal Ganglioglioma: A Case Report and Review of the Literature
por: Garnier, Louis, et al.
Publicado: (2019)

Multidisciplinary Therapy Managed Recurrent Glioblastoma in a BRAF-V600E Mutant Pregnant Female: A Case Report and Review of the Literature
por: Qin, Chaoying, et al.
Publicado: (2020)

Diagnostic Efficacy of Ultrasound, Cytology, and BRAF(V600E) Mutation Analysis and Their Combined Use in Thyroid Nodule Screening for Papillary Thyroid Microcarcinoma
por: Du, Jing, et al.
Publicado: (2022)

Comparison Between Clinicopathological Characteristics, BRAF V600E and TERT Promoter Mutation of Familial Non-Medullary Thyroid Carcinomas, and Sporadic Case
por: Yang, Tian, et al.
Publicado: (2021)

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation
por: Qu, Jingjing, et al.
Publicado: (2022)

BRAF(non-V600E) more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF(V600E) but without a survival advantage
por: Wang, Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sal79oaks8n6q43su5sh4qmqs6